Evidence map›Paper›PMID 41745108›Full record

ArticleDiseases (Basel, Switzerland)2026

Host Serum Biomarker Signatures in Mycobacteriologically Cured Pulmonary Tuberculosis Patients with Persistent Lung Inflammation on 18F-FDG PET/CT.

Bongani Motaung, Solima Sabeel, Mumin Ozturk, Trevor S Mafu, Muki Shey, Sandra L Mukasa, Karen Wolmarans, Fareda Jakoet-Bassier, Ashleigh Taylor, Antoneta Mashinyira and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bongani MotaungInstitute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Solima SabeelInstitute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0003-4200-8994
Mumin OzturkInstitute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0001-9152-7614
Trevor S MafuInstitute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Muki SheyDepartment of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0002-8776-4737
Sandra L MukasaDepartment of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Karen WolmaransDepartment of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Fareda Jakoet-BassierDepartment of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Ashleigh TaylorDepartment of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Antoneta MashinyiraGeneral Medicine & Global Health (GMGH), Cape Heart Institute, Faculty of Health Science, University of Cape Town, Cape Town 7925, South Africa.
Tessa KotzeDepartment of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0001-5362-1781
Friedrich ThienemannDepartment of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0002-4801-2030
Reto GulerInstitute of Infectious Diseases and Molecular Medicine (IDM), Department of Pathology, Division of Immunology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.

Funding

European & Developing Countries Clinical Trials Partnership RIA2017T-2004Wellcome Trust 203135/Z/16/Z
6 · The paper itself

Abstract

backgroundPulmonary inflammation is a widely recognized characteristic of active tuberculosis (TB). Although standard TB treatment is effective, a substantial proportion of mycobacteriologically cured TB patients experience persistent pulmonary inflammation, which can lead to long-term lung impairment, post-tuberculosis lung disease (PTLD) and potentially TB recurrence.

methodsWe conducted a case-control study to compare host serum biomarker profiles in individuals with minimal (TLG < 50 SUVbw*mL,

resultsFollowing multiple

conclusionWe report associations between serum inflammatory mediators and persistent pulmonary inflammation following mycobacterial clearance in TB patients, highlighting their potential as diagnostic biomarkers that could potentially meet the target product profile (TPP) criteria.

Indexed as

18F-FDG PET/CTbiomarkersinflammationpost-tuberculosis lung diseasetuberculosis

Identifiers

PMID41745108
PMCPMC12939348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.